Product Dossier
Verorab
Product Dossier for Verorab (Rabies virus, Sanofi-Aventis). ARTG record, PBS listing, PBAC outcomes, AusPAR — compiled by arcimedes.
- Sponsor: Sanofi-Aventis
- Active ingredient: Rabies virus
- Therapeutic area: Infectious Disease
- Related brand: RABIPUR
- Same area: FETROJA
- Same area: ROXAR
What it is
Verorab is a rabies virus vaccine (inactivated) supplied as 3.25 IU powder for injection in a vial with diluent pre-filled syringe with attached needle.
Approved indications
— Pre-exposure prophylaxis against rabies. — Post-exposure prophylaxis against rabies.
Regulatory history
Verorab received approval on 2022-10-06. The product was first listed on the ARTG on 2022-10-17 under licence category RE.